Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network.

BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944.

2.

Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.

Marshall I, Thrippleton MJ, Bastin ME, Mollison D, Dickie DA, Chappell FM, Semple SIK, Cooper A, Pavitt S, Giovannoni G, Wheeler-Kingshott CAMG, Solanky BS, Weir CJ, Stallard N, Hawkins C, Sharrack B, Chataway J, Connick P, Chandran S; MS-SMART Trialists.

J Neurol. 2018 Aug;265(8):1795-1802. doi: 10.1007/s00415-018-8903-y. Epub 2018 May 30.

3.

Corrigendum to "Genetic epidemiology of motor neuron disease-associated variants in the Scottish population." [Neurobiol. Aging 51 (2017) 178.e11-178.e20].

Black HA, Leighton DJ, Cleary EM, Rose E, Stephenson L, Colville S, Ross D, Warner J, Porteous M, Gorrie GH, Swingler R, Goldstein D, Harms MB, Connick P, Pal S, Aitman TJ, Chandran S.

Neurobiol Aging. 2017 Aug;56:214. doi: 10.1016/j.neurobiolaging.2017.04.019. No abstract available.

4.

The clinico-radiological paradox of cognitive function and MRI burden of white matter lesions in people with multiple sclerosis: A systematic review and meta-analysis.

Mollison D, Sellar R, Bastin M, Mollison D, Chandran S, Wardlaw J, Connick P.

PLoS One. 2017 May 15;12(5):e0177727. doi: 10.1371/journal.pone.0177727. eCollection 2017. Review.

5.

Genetic epidemiology of motor neuron disease-associated variants in the Scottish population.

Black HA, Leighton DJ, Cleary EM, Rose E, Stephenson L, Colville S, Ross D, Warner J, Porteous M, Gorrie GH, Swingler R, Goldstein D, Harms MB, Connick P, Pal S, Aitman TJ, Chandran S.

Neurobiol Aging. 2017 Mar;51:178.e11-178.e20. doi: 10.1016/j.neurobiolaging.2016.12.013. Epub 2016 Dec 21. Erratum in: Neurobiol Aging. 2017 Aug;56:214.

6.

Hypothermic Preconditioning Reverses Tau Ontogenesis in Human Cortical Neurons and is Mimicked by Protein Phosphatase 2A Inhibition.

Rzechorzek NM, Connick P, Livesey MR, Borooah S, Patani R, Burr K, Story D, Wyllie DJA, Hardingham GE, Chandran S.

EBioMedicine. 2015 Dec 12;3:141-154. doi: 10.1016/j.ebiom.2015.12.010. eCollection 2016 Jan.

7.

Hypothermic Preconditioning of Human Cortical Neurons Requires Proteostatic Priming.

Rzechorzek NM, Connick P, Patani R, Selvaraj BT, Chandran S.

EBioMedicine. 2015 Apr 11;2(6):528-35. doi: 10.1016/j.ebiom.2015.04.004. eCollection 2015 Jun.

8.

Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis.

Vesterinen HM, Connick P, Irvine CM, Sena ES, Egan KJ, Carmichael GG, Tariq A, Pavitt S, Chataway J, Macleod MR, Chandran S.

PLoS One. 2015 Apr 9;10(4):e0117705. doi: 10.1371/journal.pone.0117705. eCollection 2015.

9.

Mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in amyotrophic lateral sclerosis.

Connick P, Chandran S.

Cytotherapy. 2014 Aug;16(8):1031-2. doi: 10.1016/j.jcyt.2014.06.001. No abstract available.

PMID:
24998167
10.

Development of a high-resolution fat and CSF-suppressed optic nerve DTI protocol at 3T: application in multiple sclerosis.

Samson RS, Kolappan M, Thomas DL, Symms MR, Connick P, Miller DH, Wheeler-Kingshott CA.

Funct Neurol. 2013 Apr-May;28(2):93-100. doi: 10.11138/FNeur/2013.28.2.093.

11.

Patterns of cognitive dysfunction in progressive MS.

Connick P, Chandran S, Bak TH.

Behav Neurol. 2013 Jan 1;27(3):259-65. doi: 10.3233/BEN-120286.

12.

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S.

Lancet Neurol. 2012 Feb;11(2):150-6. doi: 10.1016/S1474-4422(11)70305-2. Epub 2012 Jan 10.

13.

Verbal fluency as a rapid screening test for cognitive impairment in progressive multiple sclerosis.

Connick P, Kolappan M, Bak TH, Chandran S.

J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):346-7. doi: 10.1136/jnnp.2010.232124. Epub 2011 Mar 2. No abstract available.

PMID:
21367765
14.

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.

Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He XL, Richardson K, Barber K, Webber DJ, Wheeler-Kingshott CA, Tozer DJ, Samson RS, Thomas DL, Du MQ, Luan SL, Michell AW, Altmann DR, Thompson AJ, Miller DH, Compston A, Chandran S.

Trials. 2011 Mar 2;12:62. doi: 10.1186/1745-6215-12-62.

15.

Stem cells as a resource for regenerative neurology.

Connick P, Patani R, Chandran S.

Pract Neurol. 2011 Feb;11(1):29-36. doi: 10.1136/jnnp.2010.235184. Review.

PMID:
21239652
16.

Lipid profile components and risk of ischemic stroke: a role for the pleiotropic effects of statins.

Connick P, Stacpoole SR.

Arch Neurol. 2010 Oct;67(10):1284-5; author reply 1285. doi: 10.1001/archneurol.2010.240. No abstract available.

PMID:
20937963
17.

Procedural confidence in hospital based practitioners: implications for the training and practice of doctors at all grades.

Connick RM, Connick P, Klotsas AE, Tsagkaraki PA, Gkrania-Klotsas E.

BMC Med Educ. 2009 Jan 12;9:2. doi: 10.1186/1472-6920-9-2.

Supplemental Content

Loading ...
Support Center